摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

一水合氢氧化钡 | 22326-55-2

中文名称
一水合氢氧化钡
中文别名
氢氧化钡一水合物;氢氧化钡单水合物
英文名称
barium hydroxide octahydrate
英文别名
dihydroxybarium octahydrate;Ba(OH)2·8H2O;Barium hydroxide hydrate;barium(2+);dihydroxide;hydrate
一水合氢氧化钡化学式
CAS
22326-55-2;12230-71-6
化学式
BaH2O2*8H2O
mdl
——
分子量
315.467
InChiKey
GKQTUHKAQKWLIN-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    78 °C(lit.)
  • 沸点:
    780°C
  • 密度:
    2.18
  • 溶解度:
    72克/升
  • 暴露限值:
    ACGIH: TWA 0.5 mg/m3NIOSH: IDLH 50 mg/m3; TWA 0.5 mg/m3
  • 物理描述:
    Barium hydroxide monohydrate is a white powder. It is slightly soluble in water. It is corrosive to metals and tissue. It is used in water purification, to make lubricating and oil additives, to make barium containing chemicals and for many other uses.

计算性质

  • 辛醇/水分配系数(LogP):
    -1.56
  • 重原子数:
    4
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    3
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • TSCA:
    Yes
  • 危险等级:
    8
  • 危险品标志:
    C
  • 安全说明:
    S26,S28,S36/37/39,S45
  • 危险类别码:
    R20/22,R34
  • WGK Germany:
    1
  • 危险品运输编号:
    UN 3262 8/PG 3
  • 海关编码:
    2816400000
  • 危险类别:
    6.1
  • RTECS号:
    CQ9200000
  • 包装等级:
    II; III
  • 危险标志:
    GHS05,GHS07
  • 危险性描述:
    H302 + H332,H314
  • 危险性防范说明:
    P260,P280,P301 + P312 + P330,P303 + P361 + P353,P304 + P340 + P310,P305 + P351 + P338

SDS

SDS:f070992585981f8f29da10b62c58e878
查看

制备方法与用途

化学性质
白色单斜晶系晶体,广泛应用于化工、轻工和医药等行业。

用途
主要用于制造钡盐。在石油工业中用作多效能添加剂,并用于生产钡基润滑脂和精制油类。此外,还用于甜菜制糖、塑料及人造丝的原料,可用作树脂稳定剂。它也被用于有机合成和其他钡盐的制造,水的软化以及玻璃和搪瓷工业。

用途
作为生产塑料的稳定剂、橡胶硫化催化剂、人造丝处理剂、锅炉硬水软化剂、矿石助熔剂等。

用途
用作合成橡胶的硬化剂、防腐剂、硬水软化剂,并精制动植物油。

用途
同样用于化工、轻工和医药行业,主要用于制造钡盐及在石油工业中作为多效能添加剂。此外,它还适用于测定空气中的二氧化碳、精制糖和动物油,以及锅炉用水清洗剂。

生产方法
硫化钡法:将重晶石焙烧后浸取得到的硫化钡溶液浓度控制在14~16°Bá,静置澄清。清液与盐酸反应生成氯化钡溶液,加热至70~90℃与过量烧碱于100~110℃进行复分解反应。经浓缩、冷却结晶、离心分离和干燥后得到八水氢氧化钡成品。

碳酸钡法:将碳酸钡与盐酸反应,控制反应液pH在4~5,浓度26~28°Bá,在80℃以上温度下反应。为避免氯化钡损失,加入过量烧碱(理论量的103%~105%)进行复分解反应。经过沉降去除铁、锰、钙等杂质后,在不断搅拌下于25℃以下冷却结晶、用冷水洗涤、离心分离和干燥得到八水氢氧化钡成品。

氯化钡法:直接以氯化钡母液为原料与苛性钠反应,随后经冷却结晶、过滤分离,得到产品。

毒重石法:将矿石粉碎后煅烧,经过浸取、过滤、净化、结晶、脱水和干燥后得到产品。

反应信息

  • 作为反应物:
    描述:
    间苯二甲酸一水合氢氧化钡 为溶剂, 反应 1.17h, 以Barium isophthalate was obtained in the form of long rods (with a length greater than 200 microns) and aspect ratios above 10的产率得到m-benzenedicarboxylate barium
    参考文献:
    名称:
    Polymeric metal terephthalate and isophthalate fibers and method of
    摘要:
    本发明公开了无水聚合金属对苯二甲酸酯和异苯二甲酸酯纤维及其制备方法,其中所述金属选自钙、钡、镁和锌组成的一组,所述纤维的平均纵横比大于约5:1。这些纤维是非常有用的添加剂,在聚合物组成物和由其制成的制品中作为性能扩展剂和/或增强剂。
    公开号:
    US05296585A1
  • 作为试剂:
    参考文献:
    名称:
    Structure−Activity Relationships of Cycloalkylamide Derivatives as Inhibitors of the Soluble Epoxide Hydrolase
    摘要:
    Structure-activity relationships of cycloalkylamide compounds as inhibitors of human sEH were investigated. When the left side of amide function was modified by a variety of cycloalkanes, at least a C6 like cyclohexane was necessary to yield reasonable inhibition potency on the target enzyme. In compounds with a smaller cycloalkane or with a polar group on the left side of amide function, no inhibition was observed. On the other hand, increased hydrophobicity dramatically improved inhibition potency. Especially, a tetrahydronaphthalene (20) effectively increased the potency. When a series of alkyl or aryl derivatives of cycloalkylamide were investigated to continuously optimize the right side of the amide pharmacophore, a benzyl moiety functionalized with a polar group produced highly potent inhibition. A nonsubstituted benzyl, alkyl, aryl, or biaryl structure present on the right side of the cycloalkylamide function induced a big decrease in inhibition potency. Also, the resulting potent cycloalkylamide (32) showed reasonable physical properties.
    DOI:
    10.1021/jm101431v
点击查看最新优质反应信息

文献信息

  • Deep-Ultraviolet Nonlinear Optics in a Borate Framework with 21-Ring Channels
    作者:Qi Wei、Jia-Jia Wang、Chao He、Jian-Wen Cheng、Guo-Yu Yang
    DOI:10.1002/chem.201602135
    日期:2016.7.25
    A new borate LiBa3(OH)[B9O16][B(OH)4], which combines the uniform porosity of open‐frameworks with the extraordinary NLO properties of borates, has been obtained under hydrothermal conditions by using mixed lithium and barium ions as templates. The framework displays an acs‐type net with large 21‐ring channels. The second harmonic generation (SHG) measurement shows that it is a type I phase‐matchable
    在水热条件下,通过混合锂和水,获得了一种新型的硼酸锂LiBa 3(OH)[B 9 O 16 ] [B(OH)4 ],它将开放骨架的均匀孔隙率与硼酸盐的非常规NLO性质相结合。钡离子作为模板。该框架显示具有大型21环通道的acs型网络。二次谐波(SHG)的测量表明,它是I型相匹配材料,具有很强的SHG信号强度,约为KDP(KH 2 PO 4的3.1倍))。UV / Vis-NIR漫反射率分析表明该化合物具有较宽的透明度范围,其短波吸收边缘低于200 nm。这些特征表明该化合物是一种很有前途的深紫外非线性光学材料。
  • Indolyl tetrahydropyridines for treating migraine
    申请人:Burroughs Wellcome Co.
    公开号:US05399574A1
    公开(公告)日:1995-03-21
    ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
    本发明涉及式(I)的化合物,其中n是0到3的整数:W是式(i)、(ii)或(iii)的基团,其中R是氢或C.sub.1-4烷基,X是--O--、--S--、--NH--或--CH.sub.2--,Y是氧或硫,式(i)或(ii)中的手性中心(*)是其(S)或(R)形式或在任何比例下的混合物:Z是式(iv)、(v)或(vi)的基团,其中R.sup.1和R.sup.2独立地选自氢和C.sub.1-4烷基,R.sup.3是氢或C.sub.1-4烷基;以及它们的盐、溶剂化物和生理功能衍生物,其制备过程,含有它们的药物以及它们作为治疗剂的用途,特别是在偏头痛的预防和治疗中。
  • Melanocortin-4 receptor binding compounds and methods of use thereof
    申请人:Millennium Pharmaceuticals, Inc.
    公开号:US20040082779A1
    公开(公告)日:2004-04-29
    Provided are MC4-R binding compounds of the formula XVII: 1 wherein L 2 is a linker group, and P 1 , P 2 , P 3 , P 4 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
    提供的是符合公式XVII:1的MC4-R结合化合物,其中L2是连接基团,P1、P2、P3、P4、Z1、Z2、Z3、Z4、Z5、t、s和R如规范所述。还提供了使用这些化合物治疗MC4-R相关疾病的方法,例如与体重减轻相关的疾病。
  • Angiotensin II antagonists
    申请人:Eli Lilly and Company
    公开号:US05612360A1
    公开(公告)日:1997-03-18
    This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    本发明提供了新型杂环衍生物,其药物配方以及在哺乳动物中对抗血管紧张素II受体的用途。
  • Alkoxylation process catalyzed by barium phosphate
    申请人:Shell Oil Company
    公开号:US04967016A1
    公开(公告)日:1990-10-30
    Alkylene oxide adducts of organic compounds having active hydrogen atoms are prepared by a process which comprises contacting and reacting an alkylene oxide reactant comprising one or more vicinal alkylene oxides with an active hydrogen containing reactant comprising one or more compounds having active hydrogen atoms in the presence of a catalytically effective amount of the compound barium phosphate. The product alkoxylates are known to be useful, for instance, as nonionic surfactants, wetting and emulsifying agents, solvents, and chemical intermediates.
    有活性氢原子的有机化合物的Alkylene oxide加合物是通过一种过程制备的,该过程包括在钡磷酸化合物的催化作用下,将包含一个或多个邻二元氧化物的Alkylene oxide反应物与包含一个或多个活性氢原子的活性氢反应物接触并反应。所得的烷氧化物被认为是有用的,例如作为非离子表面活性剂,润湿和乳化剂,溶剂和化学中间体。
查看更多